Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2026	Dec. 31, 2025
Current assets
Cash	$ 4,904,455	$ 2,077,842
Accounts receivable, net of allowances of $75,766 and $69,641 as of March 31, 2026 and December 31, 2025, respectively	248,387	217,263
Inventory	224,555	225,253
Prepaid expenses and other current assets	356,764	241,145
Total current assets	5,734,161	2,761,503
Property and equipment, net	474,641	386,165
Lease right of use	1,976,210	1,286,217
Intangible assets, net	1,369,795	1,325,145
Goodwill	6,519,232	5,878,986
Investment in NAYA Therapeutics	2,466,810	2,466,810
Total assets	24,656,147	20,220,124
Current liabilities
Accounts payable and accrued liabilities	1,668,216	2,034,057
Accrued compensation	349,957	285,946
Deferred revenue	725,493	721,897
Lease liability, current portion	271,793	208,987
Additional payments for acquisition, current portion	2,050,000	3,925,000
Warrant liability		1,881,078
Other current liabilities	47,812
Total current liabilities	6,355,838	10,331,629
Lease liability, net of current portion	1,810,504	1,171,075
Liability for excess losses of equity method investee	426,306	448,474
Notes payable – net of current portion	660,165	744,725
Other liabilities, net of current portion	79,688
Additional payments for acquisition, net of current portion	300,000	300,000
Total liabilities	9,632,501	12,995,903
Stockholders’ equity
Common Stock, $.0001 par value; 50,000,000 shares authorized; 1,640,635 and 477,366 issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	164	239
Additional paid-in capital	111,547,840	96,187,026
Accumulated deficit	(96,924,358)	(91,369,403)
Total stockholders’ equity	15,023,646	7,224,221
Total liabilities and stockholders’ equity	24,656,147	20,220,124
Series C-2 Preferred Stock [Member]
Stockholders’ equity
Preferred stock, value		2,406,359
Series D Preferred Stock [Member]
Stockholders’ equity
Preferred stock, value	400,000
Nonrelated Party [Member]
Current assets
Note receivable	5,029,770	5,029,770
Current liabilities
Notes payable	362,567	394,664
Related Party [Member]
Current assets
Note receivable	1,085,528	1,085,528
Current liabilities
Notes payable	$ 880,000	$ 880,000

Liability for excess losses of equity method investee.

No definition available.

Name:	IVF_LiabilityForExcessLossesOfEquityMethodInvestee
Namespace Prefix:	IVF_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.